Noxarem (Melatonin)

Melatonin, the active ingredient in Noxarem, is a melatonin receptor agonist presented as an oral formulation for oral use. It is used to manage insomnia, sleep onset difficulties and jet lag, primarily in adult patients who experience disrupted circadian rhythms.

GNH USA supplies Noxarem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation and responsive technical support throughout the procurement process.

Noxarem (melatonin) acts on the melatonin receptor pathway to regulate sleep‑wake cycles, making it appropriate for several sleep‑related conditions.

- Insomnia: helps reduce time to fall asleep and improve sleep continuity in adults. - Sleep onset difficulties: facilitates quicker transition to sleep by aligning the circadian rhythm. - Jet lag: assists travelers in adjusting their internal clock to new time zones, reducing daytime sleepiness.

Oral melatonin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Gastrointestinal discomfort (nausea, abdominal cramps)

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or swelling - Mood changes including depression or agitation (rare) - Hormonal effects such as altered menstrual cycles (uncommon)

When considering Noxarem, clinicians should evaluate several safety aspects to ensure appropriate use.

- Age limitation: safety in children has not been established; use is generally limited to adults. - Pregnancy and lactation: assess risk‑benefit before prescribing, as data are limited. - Concomitant CNS depressants: avoid combined use with alcohol or sedatives that may enhance drowsiness. - Underlying medical conditions: caution in patients with uncontrolled epilepsy, depression or severe hepatic impairment. - Drug interactions: review patient’s medication list for potential interactions (see interactions section). - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Melatonin can influence the activity of several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): melatonin may potentiate anticoagulant effect, increasing bleeding risk. - Immunosuppressants (e.g., cyclosporine): possible alteration of drug metabolism leading to reduced immunosuppression.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (benzodiazepines, antihistamines): additive sedative effect may require dose adjustment. - Oral contraceptives: melatonin may affect hormone levels, potentially reducing contraceptive efficacy. - Antidiabetic agents: melatonin can influence glucose metabolism, necessitating blood sugar monitoring. - CYP1A2 substrates (e.g., theophylline, fluvoxamine): melatonin may inhibit metabolism, increasing plasma concentrations.